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Purpose: Even though adipose tissue-derived stem cells (ADSCs) have been spotlighted as a possible alternative for liver 
transplantation in an experimental setting, the mechanism by which ADSCs improve liver dysfunction remains poorly 
characterized. The objective of this study was to evaluate the therapeutic ability of undifferentiated ADSCs, and find a few 
clues on how ADSCs alleviate liver damage by comparing the transplantation routes. Methods: In vitro generated human 
ADSCs were checked for surface markers and stage-specific genes for characterization. Afterwards, they were transplanted 
into C57BL/6 mice with CCl4-induced liver injury. The transplantations were made via tail vein, portal vein, and direct liver 
parenchymal injection. At 1 and 3 post-transplantation days, serum biochemical parameters and/or liver specimens were 
evaluated. Results: We have shown here that ADSCs have the characteristics of mesenchymal stem cells, and belong to endo-
dermal and/or early hepatic differentiation stage. After transplantation into the mice with acute liver failure, markers of liver 
injury, such as alanineaminotransferase, aspartateaminotransferase, as well as ammonia, decreased. Of these transplantation 
routes, transplantation via tail vein rendered the most prominent reduction in the biochemical parameters. Conclusion: 
Undifferentiated ADSCs have the ability to improve hepatic function in mice with acute liver injury. Moreover, our trans-
plantation route study supports the theory that ADSCs in systemic circulation can exert endocrine or paracrine effects to 
ameliorate the injured liver.
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INTRODUCTION
At present, liver transplantation is considered as the 
best curative option for end-stage liver diseases. However, 
the limitations of liver transplantation, such as the short-
age of organ donors, have made the process long and diffi-
cult for peri-transplantation courses. Therefore, the ad-
verse effects caused by life-long immunosuppressive regi-
mens have prompted the efforts to find the alternative. 
Hepatocyte transplantation was first considered, how-Adipose tissue-derived stem cells for liver failure
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ever, it also faced several difficulties, which include the 
unsolved problem of donor shortage, troublesome proc-
esses of cultivation, and requirement of immunosuppress-
ive regimens. Under these circumstances, many inves-
tigators have researched stem cell transplantation with the 
hope of overcoming these limitations. 
Of all the possible stem cell lines, we paid attention to 
the adult stem cells, especially mesenchymal stem cells 
(MSCs). MSCs were proven to have the ability to pro-
liferate extensively, and to differentiate into multiple cell 
types [1,2]. In addition, MSCs are known to circumvent 
immunocompatibility problems because they have low 
expressions of human leukocyte antigen (HLA) I and no 
HLA II, as well as a low risk of allogenic rejection and 
graft-versus-host disease [3,4]. Various tissues, such as the 
bone marrow, amniotic fluid, placenta, umbilical cord 
blood, scalp tissue, placenta, and adipose tissue, were 
known to contain MSCs [5-9].
In our study, we intended to evaluate the therapeutic 
potential of the adipose tissue. Zuk et al. [9,10] first dem-
onstrated the adipse tussue-derived stem cells’ (ADSCs) 
potential for a multi-lineage differentiation, and Seo et al. 
[11] reported the first successful hepatocytic differ-
entiation from ADSCs. Thereafter, numerous trials have 
applied ADSCs into hepatic failure animal models and 
demonstrated the therapeutic potentials of ADSCs trans-
plantation [12-17]. However, the exact mechanism by 
which ADSCs improve the liver dysfunction in a hepatic 
injured animal model remains to be clarified. Most re-
searchers have focused on the possibility that the trans-
planted ADSCs become engulfed in the liver, where they 
act as hepatocyte through transdifferentiation or fusion 
[11,12,14-17]. Therefore, they have attempted to establish 
differentiated ADSCs in vitro prior to a transplantation. 
However, it also has been proposed that MSCs act as tro-
phic mediators, by which they secrete bioactive factors to 
ameliorate the liver damage [13,18]. To prove this ADSCs’ 
hormonal effect, the therapeutic effect of undifferentiated 
ADSCs should first be demonstrated. Therefore, the pur-
pose of this study was to evaluate the therapeutic ability of 
undifferentiated ADSCs, and find a clue on how ADSCs 
alleviate liver damage by comparing the transplantation 
routes.
METHODS
Stem cell isolation and culture 
Adipose tissues were obtained from 3 different donors 
(donor 1: female, 33 years old; donor 2: female, 17 years 
old; donor 3: male, 13 years old) undergoing appendec-
tomy or cholecystectomy. The hospital’s ethics committee 
approved this study and informed consents were obtained 
from all the patients. To isolate ADSCs, adipose tissues 
were washed with equal volumes of phosphate-buffered 
saline (PBS) and digested at 37
oC for 30 minutes with 
0.075% collagenase type I (Sigma-Aldrich Co., St. Louis, 
MO, USA). Enzyme activity was neutralized with Dulbec-
co’s modified Eagle’s medium (DMEM)/F-12 (Invitrogen, 
Carlsbad, CA, USA) containing 10% fetal bovine serum 
(FBS; Invitrogen). Adipose tissue cells were filtered 
through a 100-μm nylon mesh to remove the cellular 
debris. Cell suspension was centrifuged for 10 minutes to 
obtain a pellet and cultured at 37
oC/5% CO2 in culture me-
dia (DMEM/F-12, 10% FBS, and 100 U/mL penicillin/ 100 
μg/mL streptomycin). Following the incubation, the plates 
were washed with PBS to remove the residual non-adher-
ent red blood cells. The resulting cell population was con-
sidered as stromal vascular fraction, and banked in 
DMEM/F-12 containing 10% FBS. After thawing, cells 
were cultured at 37
oC/5% CO2 in DMEM/F-12 containing 
10% FBS culture media. Adherent cells were maintained in 
culture, and the media were changed every 2 days. Upon 
reaching an 80% confluence, the cells were digested with 
0.25% trypsin/ethylenediaminetetraacetic acid at 37
oC, 
centrifuged and resuspended in the media. The cell sus-
pensions were plated in new flasks and remained in the 
culture. After 3 passages, the cells were used for analysis.
Identification of cell characteristics
Flow cytometry
ADSCs were analyzed by flow cytometry for cell sur-
face antigen expression. Passage-three cells were in-
cubated with fluorescein isothiocyanate- or phycoery-
thrin-conjugated anti-CD44, anti-CD45, anti-CD29 or 
mouse immunoglobulin G isotype control antibodies (BD 
Biosciences, Heidelberg, Germany) for 30 minutes at 4
oC Say-June Kim, et al.
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Fig. 1. Study design. SL, saline infusion via tail vein; PV, 
transplantation via portal vein; TV, transplantation via tail vein; LP, 
transplantation via direct liver parenchyma infusion.
in PBS. Cells were washed and analyzed by a FACSCalibur 
kit (BD Biosciences).
Reverse transcriptase-polymerase chain reaction (RT-PCR)
To determine which developmental stage - endodermal 
stage, early hepatic differentiation stage, or mature hep-
atocyte stage - the ADSCs belong to, RT-PCR was per-
formed. In order to make a proper comparison, we at-
tempted an endodermal induction for ADSCs [12,19]. 
Thereafter, ADSCs without an endodermal induction 
were compared against ADSCs with an endodermal in-
duction. For an endodermal induction, the cells were 
treated for 3 days with DMEM/F-12, (serum free) supple-
mented with 20 ng/mL Activin A (R&D Systems Inc., 
Minneapolis, MN, USA) and 10 ng/mL FGF4 (PeproTech 
EC Ltd., London, UK). Total RNA was extracted from 
ADSCs using a TRIzol kit (Invitrogen). RNA integrity was 
examined by agarose gel electrophoresis. cDNA was syn-
thesized using 2 mg of total RNA and random primers. 
GAPDH was used as a reference gene. Specific PCR prod-
ucts (Bioneer, Daejeon, Korea) were generated using 5 
pmol sense and antisense primers as indicated below: 
GATA4: sense, 5’-TTCCTC TTCCCTCCTCAA AT-3’ and 
anti-sense, 5’-TCA GCG TGT AAA GGC ATC TG-3’; 
FOXA2: sense, 5’-GGGAGCGGTGAAGATGGAAG-3’ and 
anti-sense, 5’-TGCCAGCGCCCACGTA-3’; α-Fetopro-
tein  (AFP): sense, 5’-AACAAGTATGGATTCTCAGG-3’ 
and anti-sense, 5’-ATTGATGCTCTCTTTGTCTG-3’; HNA- 
4α: sense, 5’-GAGCAGGAATGGGAAGGA TG-3’ and an-
ti-sense, 5’-GGCTGTCCTTTGGGATGA AG-3’; and GAPDH: 
sense, 5’-TCCATGACA ACTTTGGTATC-3’ and anti- sen-
se, 5’-TGTAGCCAAATTCGTTGTTA-3’, based on human 
genome database (National Center for Biotechnology 
Information). 
ADSCs transplantation into mice with CCl4- in-
duced injury
4, 6-diamidino-2-phenylindole (DAPI) labeling
For the identification of ADSCs after the transplan-
tation, ADSCs nuclei were stained using DAPI (Sigma- 
Aldrich). DAPI was added to the media to a final concen-
tration of 50 mg/mL. The cells were incubated at 37°C un-
der 5% CO2 for 30 minutes, then washed six times in PBS. 
Cells were detached by digestion with 0.25% tryp-
sin/EDTA at 37




Transplantation into mice with CCl4-induced injury
Animal studies were carried out in compliance with the 
guidelines of the Institute for Laboratory Animal Rese-
arch, Korea. Eight-week-old male C57BL/6 mice (Damool 
Science, Daejeon, Korea) were used. Experimental mice 
were largely divided into 2 groups: control group (saline 
infusion group; SL group = 5) and transplantation group 
(TR group, n = 15). TR group was further divided accord-
ing to the transplantation routes; transplantation via tail 
vein (TV; n = 5), transplantation via portal vein (PV; n = 5), 
and transplantation via direct liver parenchyma infusion 
(LP; n = 5) groups (Fig. 1). Acute liver failure model was 
produced by giving an i.p. injection of 100 mL/20 g body-
weight of olive oil containing 10 mL CCl4 at day 0. The con-
trol group received i.p. injection of 100 mL/20 g body-
weight of olive oil without CCl4. At day 1, mice underwent 
a transplantation of ADSCs at a concentration of 1.5 × 10
6 
cells per mouse. The transplantation routes were different 
according to each TR group. Specifically, in the PV group, 
the transplantation was performed after the midline lapa-
rotomy under i.v. ketamine anesthesia. Spleen was ex-Adipose tissue-derived stem cells for liver failure
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Fig. 2. Morphology of adipose 
tissue-derived stem cells (ADSCs) 
before (A) and after (B) endo-
dermal induction (x100 magni-
fication). ADSCs initially had 
spindle-like appearance progres-
sively changing into an oval shape 
after endodermal induction.
posed using a wet cotton swab. A purse-string suture us-
ing a prolene 6-0 (Ethicon Inc., Somerville, NJ, USA) was 
made around a presumed infusion site. Then, ADSCs 
were infused slowly for 1 minute, and thereafter, the 
purse-string suturing was completed. In the LP group, the 
same laparotomy as the PV group was made. After putting 
a superior lobe aside, the infusion was solely performed 
into a medial lobe after the placement of purse-string 
suture. After the infusion, purse-string suturing was 
completed. Lastly, in TV the group, transplantation was 
made via tail vein without anesthesia.
Accessment of transplantation outcome 
Serum biochemical markers
Blood samples were obtained from each mouse at 1 day 
and 3 days after the transplantation, centrifuged for 20 mi-
nutes at 400 g, and its serum was collected. The concen-
tration of biochemical parameters such as aspartate ami-
notransferase (AST), alanine aminotransferase (ALT), and 
ammonia were analyzed by using a IDEXX VetTest Che-
mistry Analyzer (IDEXX Laboratories Inc., Westbrook, 
ME, USA).
Hematoxylin-esosin (HE) stain & immunohistochemistry
HE staining was performed to find the changes in histo-
logical architecture, and Ki67 stain was followed to eval-
uate the degree of proliferation. Liver specimens were pre-
pared at Day 1 post-transplantation, and each specimen 
was stained into hematoxylin-esosin stain and Ki 67 stain, 
respectively. For Ki67 immunohistochemistry, paraffin- 
embedded tissue sections were deparaffinized in xylene 
and rehydrated in a graded series of alcohol. The antigen 
was retrieved with 0.01M citrate buffer (pH 6.0) by heating 
the sample in autoclave (CHS-ACCE-860, JW Pharmaceut-
ical, Seoul, Korea) at a controlled final temperature of 
121
oC for 25 minutes. The tissue sections were then placed 
in 3% hydrogen peroxide for 5 minutes to inactivate the 
endogenous peroxidase, and blocked for 10 minutes with 
normal horse serum (DakoCytomation LSAB2 System- 
HRP kit; DakoCytomation, Glostrup, Denmark). The pri-
mary antibody used for this study was Ki-67 mouse mono-
clonal antibody (Clon MIB-1, 1:100; DakoCytomation). All 
the pre-diluted primary antibodies were applied for 30 mi-
nutes at room temperature. The slides were then treated 
with biotinylated secondary antibody for 10 minutes at 
room temperature, followed by Streptavidin-HRP and 
3,3'-diaminobenzidine solution for another 10 minutes at 
room temperature. Tissue sections were counter-stained 
with hematoxylin.
Statistical analysis
All data were analyzed with SPSS ver. 11.0 (SPSS Inc., 
Chicago, IL, USA), and are presented as mean ± SD or me-
dian (range). A P-value ＜  0.05 was considered significant.Say-June Kim, et al.
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Fig. 3. Flow cytometry of adipose tissue-derived stem cells (ADSCs) with mesenchymal and hematopoietic stem cell markers. Mesenchymal 
stem cell markers (CD29, CD105, and CD166) were expressed whereas hematopoietic stem cell marker (CD34) was not.
Fig. 4. Genes related to hepatic differentiation determined by 
reverse transcription-polymerase chain reaction. Adipose-tissue 
derived stem cells (ADSCs), both before and after the endodermal 
induction, expressed GATA4, FOXA2, and AFP genes, and did not 




ADSCs were cultivated in DMEM/F-12 containing 10% 
FBS, and were replated when they reached an 80% 
confluence. ADSCs initially appeared as a spindle shape, 
reminding of fibroblasts (Fig. 2A). After the 3-day endo-
dermal Activin A and FGF4 induction period, this fibro-
blast-like morphology was progressively changed into an 
oval shape (Fig. 2B). 
Flow cytometry
To specify the antigenic properties of ADSCs, cell sur-
face protein expression was determined by flow cyto-
metry. Flow cytometric analysis confirmed the expres-
sions of the MSC markers (CD29, CD105, and CD166) in all 
three donors, however not the hematopoietic stem cell 
marker (CD34) (Fig. 3). 
RT-PCR
Gene expression of undifferentiated ADSCs was com-Adipose tissue-derived stem cells for liver failure
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Fig. 5. Engulfment of 4, 6-diami-
dino-2-phenylindole (DAPI)-labe-
led adipose tissue-derived stem 
cells (ADSCs) in mouse liver accor-
ding to different transplantation 
routes. Mice with acute liver injury 
were transplanted with DAPI-la-
beled ADSCs injected through tail 
vein (TV group) (A), portal vein (PV 
group) (B), and direct liver 
parenchyma (LP group) (C). Panels 
show fluorescent microscopic views 
of representative liver sections 
obtained one day after the trans-
plantation (×100 magnification). The 
number of DAPI-positive cells of the 
TV group was comparable to the 
number of the PV group (D). How-
ever, the number of DAPI- positive 
cells of the TV group was signi-
ficantly higher than that of the LP 
group (P = 0.026).a)
pared with the gene expression of ADSCs which had 
passed an endodermal induction. In both groups, genes 
related with endodermal stage (GATA4) and early hepatic 
differentiation (FOXA2, AFP) were expressed. However, 
genes related with mature hepatocyte (Albumin, HNF-4α) 
were not (Fig. 4). 
ADSC transplantation into mice with liver failure
DAPI immunofluoresence
ADSCs labeled by DAPI had round or oval light blue 
spots when viewed under the fluorescence microscope, 
and most ADSCs appeared to be labeled. We transplanted 
1.5 × 10
6 cells of DAPI-labeled ADSCs into the CCl4-injured 
mice by 3 different ways; via tail vein (TV group), portal 
vein (PV group), and directly liver parenchyma (LP 
group). Liver specimens were obtained 24 hours after the 
transplantation to certify the distribution of DAPI-pos-
itive cells in each group. In the TV group, DAPI-positive 
cells were found to be evenly distributed under the fluo-
rescence microscope (Fig. 5A). In the PV group, DAPI-pos-
itive cells were observed in clusters, scattered throughout 
every lobe of the liver (Fig. 5B). In the LP group, DAPI-pos-
itive cells were mainly restricted in the injected lobe, form-
ing a cluster nature (Fig. 5C). To estimate the amount of en-
gulfed ADSCs according to each transplantation route, the 
number of DAPI-positive cells was counted in 5 random-
ized views of the liver sections. The mean numbers of 
DAPI-positive cells in the TV, PV, and LP group were 48.0 
± 5.7, 43.4 ± 3.1, and 38.2 ± 5.5, respectively (Fig. 5D). The 
number of DAPI-positive cells in the TV group was com-
parable to the number in the PV group. However, the LP 
group showed the least amount of prominent ADSCs en-
gulfment among these groups (P = 0.026).Say-June Kim, et al.
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Fig. 6. Comparison of histological 
changes according to transplan-
tation routes. The histological sec-
tions were stained into two ways; 
H&E stain (A-D) and Ki67 im-
munohistochemical stain (E-H). 
Panel (A-D) represents the changes 
in the centrilobular necrosis area 
(red ellipse) observed after the sa-
line infusion via tail vein (A), the 
transplantion of ADSCs via tail vein 
(B), portal vein (C), and direct liver 
parenchyma infusion (D). Panel (E- 
H) represents the changes in the 
occurrence of Ki67-positive nuclei 
(arrow; brown spot) observed after 
the saline infusion via tail vein (A), 
the transplantion of ADSCs via tail 
vein (B), portal vein (C), and direct 
liver parenchyma infusion (D).
Histological staining
HE staining was performed to find the changes in histo-
logical architecture, and Ki67 stain was followed to eval-
uate the degree of proliferation. Normal mouse liver 
showed well-organized hepatic cords in a HE stain, and 
unstained nuclei in a Ki67 stain suggested a low pro-
liferation status (control group). Twenty-four hours after 
the CCl4 injection, centrilobular necrosis was observed in 
a HE stain (HF group). Additionally, no nucleus was 
stained with Ki67 stain in the HF group. Histological 
stains were obtained 24 hours after the transplantation. In 
the TV group, reduction of the necrosis area was observed Adipose tissue-derived stem cells for liver failure
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when it was compared to the SL group, and several nuclei 
stained with Ki67 emerged. Such an improvement - the re-
duction of the necrosis area, and the emergence of Ki67 
stained nuclei- was also observed in the TV and LP group. 
The degree of improvement was most prominent in the TV 
group, followed by the PV group, the LP group, re-
spectively (Fig. 6).
Biochemical parameters
Twenty-four hours after the CCl4 i.p. injection, bio-
chemical parameters such as AST, ALT, and ammonia 
were significantly increased in the HF group, when it was 
compared to the control group. Next, we evaluated the 
therapeutic potential according to the transplantation 
routes (Fig. 7). One day after the ADSCs transplantation, 
AST and ALT values of the TV group and PV group were 
significantly lower compared to the measurements in the 
SL group (in AST values, 760 IU/L [980 - 640], 1050 IU/L 
[1,320 - 980] versus 1,585 IU/L [1,890 - 1,110], P ＜  0.05; in 
ALT values, 620 IU/L [1,300 - 360], 1,000 IU/L [1,100 - 800] 
versus 1,200 [2,470 - 850], P ＜  0.05) (Fig. 7). And, 3 days af-
ter the transplantation, AST and ALT of the all TR groups 
(TV, PV, and LP group) were significantly lower than the 
values of SL group (in AST values, 260 IU/L [280 - 185], 370 
IU/L [560 - 110], and 570 IU/L [740 - 320] versus 980 IU/L 
[1,230 - 450], P ＜ 0.05). Of the TR groups, one day after 
transplantation, the TV group showed the most prom-
inent reduction in the biochemical parameters than the PV 
and LP groups (in AST values, 760 IU/L [980 - 640] versus 
1050 IU/L [1,320 - 980], 1,320 IU/L [1,530 - 1,120], P ＜  0.05; 
in ALT values, 620 IU/L [1,300 - 360] versus 1,000 [1,100 - 
800], 1,020 [1,360 - 820], P ＜  0.05). Likewise, ammonia con-
centrations of the TR groups were lower than the concen-
trations of the SL group, though this difference did not 
reach a statistical significance.
Fig. 7. Comparison of biochemical parameters including aspartate 
aminotransferase (AST) (A), alanine aminotransferase (ALT) (B), 
and ammonia (C) according to transplantation routes. The means 
and standard deviations were demonstrated. Of the 3 different 
transplantation route groups, the TV group (adipose tissue- 
derived stem cells transplantation via tail vein) showed the most 
prominent reduction in the AST and ALT values (P ＜0.05). SL,  
saline infusion group; PV, transplantation via portal vein; TV, 
transplantation via tail vein; LP, transplantation via liver paren-
chyma. Say-June Kim, et al.
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DISCUSSION
The shortage of organ donors and other substantial lim-
itations of liver transplantation have caused many re-
searchers to find an alternative option. Ever since the plu-
ripotency and reproducibility of the stem cells have been 
disclosed [20], many investigators have hoped to alleviate 
liver diseases by a stem cell transplantation. Therefore, 
many experiments have been carried out. However, 
there’s still a long way to go since there is still no consensus 
on the stem cell source, the transplantation route, or even 
the appropriate amount of the stem cells. Of all the avail-
able stem cell sources, MSCs have been spotlighted, possi-
bly due to its affluence and easy approachability [21]. We 
paid our attention to the adipose tissue as a possible MSC 
source for following reasons. First, extra procedure to at-
tain the tissue is usually not required because adipose tis-
sues can easily be harvested in the process of a common 
surgical procedure, such as appendectomy and cholecy-
stectomy. Furthermore, we could also utilize the omental 
patch which is removed during the abdominal cancer 
operations. Next, the stem cell yield from the adipose tis-
sue is known to be, maximally, about 40 times more than 
the yield from the bone marrow [22,23]. Lastly, in-vitro ex-
pansion of ADSC can be performed conveniently.
Over the past two decades after the discovery of stem 
cells in the adipose tissue [9], the therapeutic potential of 
ADSCs to the liver disease have been explored. However, 
numerous reports focused on the hepatic differentiation of 
ADSCs, because they thought that the ADSCs’ therapeutic 
potential originated from the functionally differentiated 
stem cells. However, it was also known that stem cells can 
act as paracrine or endocrine cells to affect adjacent cells by 
secreting bioactive factors. Rehman et al. [18] reported that 
adipose stromal cells, which had been obtained from hu-
man subcutaneous adipose tissue, secreted considerable 
amount of vascular endothelial growth factor, hepatocyte 
growth factor, and transforming growth factor-β. More-
over, Banas et al. [13] later observed that ADSCs secreted a 
higher volume of interleukin 1 receptor α (IL-1Rα), IL-6, 
IL-8, granulocyte colony-stimulating factor (G-CSF), gran-
ulocyte-macrophage (GM-CSF), monocyte chemotactic 
protein 1, and nerve growth factor than MSCs originated 
from either the bone marrow or human dermal fibroblasts 
did. In our study, we demonstrated a definite decline in 
the liver enzyme levels after an undifferentiated ADSC 
transplantation. The changes were observed one day after 
the transplantation, and became prominent 3 days after 
the transplantation. Because a 24-hour period is not suffi-
cient for ADSCs to differentiate into full-grown hep-
atocytes, it is natural to think that the systemic changes in-
duced by ADSCs might have contributed to it. Our ob-
servation was also in line with other reports [13,16]. We 
think that our result provides a substantial meaning when 
it is applied to a clinical setting. Acute liver failure is a cat-
astrophe which can lead to death. Moreover, there is a very 
limited time window to treat and save the patients. 
However, inducing a hepatic differentiation needs fixed 
time, ranging from 2 weeks to several months [11,12,14-17]. 
Therefore, it is our opinion that if the undifferentiated 
ADSCs’ effectiveness can be proved in a clinical setting, a 
number of patients can receive a potentially life-saving 
treatment within that small window of time. 
In this experiment, the therapeutic potentials according 
to the transplantation route were compared. Until now, in 
most studies, ADSC transplantations have been at-
tempted by a peripheral vein [11-14,17], and uncommonly, 
via portal vein [15] and direct liver parenchyma [16]. We 
think that a study of the transplantation route can give es-
sential information about how ADSCs influence the in-
jured liver. After a liver injury, a systemic change occurs 
[24-29]; the SDF-1, G-CSF, and other mediator expressions 
increase in the peripheral blood, whereas the SDF-1 and 
CXCR4 expressions in the bone marrow decrease because 
of neutrophil protease. These changes lead to the recruit-
ment of MSCs and hematopoietic stem cells into the pe-
ripheral blood, ending up reaching the liver. During this 
process, the hepatic damage is thought to be ameliorated 
by the ADSCs’ endocrine and/or paracrine effects. In our 
study, whereas transplanted ADSCs via tail vein even-
tually reach the liver by way of the blood stream, trans-
plantations via other routes - portal vein and direct liver 
parenchyma - bypass the systemic circulation. Therefore, 
bypassing the systemic circulation in PV group and LP 
group is thought to be the cause of lesser prominent liver 
repairing effects in these groups.Adipose tissue-derived stem cells for liver failure
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We found several differences according to the trans-
plantation route. First, there was a noticeable difference in 
the liver’s ADSCs distribution; whereas the TV group 
showed evenly scattered ADSCs in the liver, the PV group 
and the LP group demonstrated clustered ADSCs along-
side the portal vein or the injected site, respectively. Next, 
we observed that the engulfed amount of tail-vein trans-
planted ADSCs was not lesser than the engulfed amount 
of portal vein transplanted ADSCs, even though tail-vein 
transplanted ADSCs reached the liver by way of the sys-
temic circulation. One explanation could be that the che-
motactic factors, which had been released from the injured 
liver, effectively attracted the ADSCs [27,30]. Lastly, of 
these three different transplantation route groups, the TV 
group showed the most prominent reduction in the bio-
chemical parameters. Therefore, we think the bioactive 
factors in the TV group might have contributed to this 
phenomenon.
In conclusion, we demonstrated that undifferentiated 
ADSCs were able to improve the hepatic function in mice 
with acute liver injury within a short span of time. Since 
there was not a sufficient time period for the ADSCs to dif-
ferentiate into full-grown hepatocytes, it is natural to think 
that the ADSCs induced hormonal changes favorable to 
the liver function. We also observed that the transplan-
tation via peripheral vein resulted in a more prominent 
liver function than the transplantation via other routes. 
This finding also supports the ADSCs’ hormonal effect be-
cause the ADSCs transplanted via peripheral vein had rel-
atively longer time to stay in the systemic circulation than 
the ADSCs transplantated via other routes. However, for 
the clinical application, further and more extensive stud-
ies are necessary to confirm these findings as well as to 
clarify exactly how ADSCs improve the liver function. 
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